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Summary
 Aim Satisfactory performance of modern data processing methods, namely princi-
pal component analysis (PCA) and artiﬁ cial neural network (ANN) analysis, has 
been demonstrated in the prediction of the results of surgical treatment for en-
dometrial carcinoma.
 Materials/Methods The data from 121 patients treated and observed in one oncology unit was retrospec-
tively evaluated. 26 subject and treatment variables were determined for each pa-
tient. A matrix of 121×26 data points was subjected to PCA and ANN processing.
 Results The properly trained ANN was used to predict whether patients belonged to 
the group of those who survived, or to the group of those who did not survive, a 
5-year period. It was found that the prognostic capability of the ANN, regarding 
the tested set of patients, was very high. Additionally, using the principal com-
ponent analysis (PCA) method, two principal components, PC1 and PC2 were 
extracted and accounted, cumulatively, for 23% of the variance in the data an-
alyzed. An apparent clustering of the variables and a clear cut clustering of the 
patients was observed, which has been interpreted in terms of similarity, or dis-
similarity, of the variables and of the patients.
 Conclusions It has been concluded that ANN analysis offers a promising alternative to estab-
lished methods for the statistical analysis of multivariate data in cancer patients. 
Also, PCA has been recommended as a new and promising alternative to classi-
cal regression analysis of multivariate clinical data. By means of PCA, practically 
useful systematic information may be extracted from large sets of data, which is 
otherwise hardly interpretable in comprehensive physical terms. Such informa-
tion can be of value for general prognosis and for making appropriate adjust-
ments in treatment.
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BACKGROUND
Endometrial carcinoma is the most common 
cancer of the female reproductive system in the 
United States. It accounts for 6% of all female 
cancers in this country. The general choice of 
treatment depends on the stage of the disease, 
hormonal status, and patient age, among oth-
ers [1]. The therapeutic strategy depends on the 
prediction of outcome and response to therapy. 
However, a reliable prediction of the results of 
treatment is extremely difﬁ cult because of the 
lack of single prognostic parameters or identi-
ﬁ ed combinations of these [2].
Several factors have been recommended to help in 
the prognosis of both overall survival and the re-
currence-free interval in patients with various types 
of cancer, including cancer of the uterus [3–9]. 
Endometrial carcinoma is the ﬁ fth most common 
among Polish women and the frequency with which 
it is diagnosed is rising [10]. According to the new 
classiﬁ cation of the International Federation of 
Gynecology and Obstetrics (FIGO) (1988), in or-
der to evaluate the proprietary stage of endome-
trial cancer maturity, one must perform a total 
hysterectomy with bilateral salpingo-oophorecto-
my and peritoneal cytology, as traditionally per-
formed, in addition to a pelvic and para-aortic lym-
phadenectomy. The appearance of malignant cells 
in these groups of lymph nodes affects the clini-
cal stage of the cancer and is evidence for likely 
spread [11,12]. This provides information regard-
ing the spread of the cancer and also decreases the 
number of women who must subsequently under-
go supplementary radiotherapy. The excision of 
the lymph nodes with metastases has diagnostic as 
well as therapeutic advantages. However, surgical 
treatment including lymphadenectomy in older, 
overweight patients, with additional diseases such 
as diabetes and hypertension comes with increased 
risk [13,14]. Hence, it is postulated that it may be 
of value to individualize the the decision regard-
ing lymphadenectomy, and to broaden the treat-
ment possibilities by means of clinical and histo-
logical prognostic factors.
The fundamental problem with multiple regres-
sion analyses is that the parameters (independ-
ent variables) considered simultaneously cannot 
be mutually related [15]. To ﬁ nd a representa-
tive and, for statistical purposes, sufﬁ ciently large 
set of suitable treatment parameters is difﬁ cult. 
Therefore, prognostic indices derived by means 
of multiple regression analysis are of rather lim-
ited reliability.
Artiﬁ cial neural network (ANN) analysis is a new 
method, which aims to emulate the working of 
the brain. ANNs differ from classical computer 
programs in that they “learn” from a set of ex-
amples, rather than being programmed to get 
the right answer. The information is encoded in 
the strength of the network’s “synaptic” connec-
tions [16,17]. In chemistry and related ﬁ elds of 
research interest, neural-network computing has 
been described since 1986 [18,19]. ANNs found 
applications in compound classiﬁ cation, mode-
ling of structure-activity relationships, identiﬁ ca-
tion of potential drug targets and the localization 
of structural and functional features of biomole-
cules [20–23]. ANNs have been proposed as deci-
sion support systems in dentistry [24], in urology 
[25–27], and to assess HIV/AIDS-related health 
performance [28].
The general idea of principal component analy-
sis (PCA) is to reduce the dimensionality of the 
original multivariate data set by ﬁ nding linear 
combinations of those variables that best ex-
plain the variability within the set of data con-
sidered. By means of PCA, systematic informa-
tion, initially dispersed over a large matrix of 
input variables (often intercorrelated), is extract-
ed and condensed into a few abstract variables. 
Projections of data points ascribed to individu-
al objects (patients) and to individual variables 
reﬂ ect mutual similarities and dissimilarities 
among them [18].
The purpose of this work was to prove that ANN 
and PCA are convenient and reliable prognos-
tic tools, using the example of surgical treatment 
 Full-text PDF: http:/www.rpor.pl/pdf.php?MAN=8254
 Word count: 1480
 Tables: 5
 Figures: 5
 References: 28
 Author’s address: Adam Buciński, Collegium Medicum in Bydgoszcz, Department of Biopharmacy, Jagiellońska 13 Str., 
85-067 Bydgoszcz, Poland, e-mail: kizbiofarmacji@cm.umk.pl
Original Paper Rep Pract Oncol Radiother, 2005; 10(5): 239-248
240
results in endometrial carcinoma. By this meth-
od, one can exploit all of the available informa-
tion on a patient, disease and treatment, making 
use of a single analysis of the variables ranging 
from sociology to genetics. In this project the ap-
proach was tested on the material available for 
121 endometrial carcinoma patients who were 
treated and observed in the Surgical Gynaecology 
Department of the Specialist Provincial Hospital 
in Olsztyn.
No. Variable name
1 Age (years)
2 Year of surgery
3 Place of residence: Village (0), City (1)
4 Marital status: Widow (0), Married (1), Single (2)
5 Education: Secondary (0), Higher (1), Elementary (2)
6 Professional activity: Pension (0), Employed (1), Unemployed (2)
7 Blood group: A (0), B (1), AB (2), 0 (3)
8 Number of deliveries
9 Number of miscarriages
10 Age at fi rst menstruation (years)
11 Age at last menstruation (years)
12 Postmenopausal diagnosis: Yes (0), No (1)
13 Obesity: Yes (0), No (1)
14 Arterial hypertension: No (0), Yes (1)
15 Diabetes mellitus: No (0), Yes (1)
16 Endometriosis: Internal (0), No (1), Neoplasia in endometriosis (2), External (3)
17 Uterine myoma: No (0), Yes (1)
18
Scrapings histological type: Adenocarcinoma (0), Hyperplasia atypica end. in carcinoma vertens (1), Adenocarcinoma bene diﬀ erentiatum 
end. (2), Adenocarcinoma male diﬀ erentiatum end. (3), Hyperplasia atypica end. cum atypia gr. maioris (4), Neoplasma malignum (5), 
Adenocarcinoma mediocriter diﬀ erentiatum (6) Adenocarcinoma clarocellulare (7), Absence of cancer cells in pre-operational material (8)
19
Histologic type of post-operational material: Absence of cancer cells in pre-operational material (0), Adenocarcinoma mediocriter 
diﬀ erentiatum(1), Adenocarcinoma bene diﬀ erentiatum end. (2), Adenocarcinoma male diﬀ erentiatum end. (3), Carcinoma adenosquamosum 
(4), Adenoacanthoma (5), Carcinoma solidum (6), Hyperplasia atypica end. in carcinoma vertens (7), Hyperplasia atypica end. cum atypia gr. 
mediocri (8), Adenocarcinoma clarocellulare (9)
20 Endometrial carcinoma histological grading: G 1 (0), G 2 (1), G 3 (2)
21 Endometrial carcinoma staging: I A (0), I B (1), I C (2), II A (3), III A (4), II B (5), IV B (6), IV A (7), III C (8)
22 Occurrence of other neoplasms: No (0), Malignant (1), Benign (2)
23
Kind of applied surgical treatment: Total abdominal hysterectomy with bilateral salpingo-oophorectomy (0), Total abdominal hysterectomy 
with bilateral salpingo-oophorectomy + peritoneal cytology (1), Total abdominal hysterectomy (2), Amputation of the body of the uterus 
with bilateral salpingo-oophorectomy (3), Total abdominal hysterectomy with bilateral salpingo-oophorectomy + peritoneal cytology + 
pelvic and paraaortic lymphadenectomy (4)
24 Depth of myometrial invasion: Limited to endometrium (0), < 1/2 muscle thickness (1), > 1/2 muscle thickness (2)
25 Vascular space invasion: No (0), Yes (1)
26 Colpitis: No (0), Yes (1)
Class Category: Did not surviv 5 years after operation (0), Survived 5 years after operation (1)
Table 1. Variables considered in an analysis by an artiﬁ cial neural network (ANN).
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MATERIALS AND METHODS
Patients
Data on 121 patients with endometrial carcino-
ma was retrospectively collected and analyzed. 
The variables considered in this study are pre-
sented in Table 1. A total number of 26 variables 
were subjected to ANN and PCA analyses. The 
ﬁ nal matrix of data subjected to ANN and PCA 
analysis therefore consisted of 121 patients mul-
tiplied by 26 variables. Table 2 presents the data 
for six selected patients: surviving or not surviv-
ing a 5-year period after surgical treatment.
ANN analysis
Artiﬁ cial neural networks (ANN) were run on 
a personal computer using Statistica Neural 
Networks software (StatSoft, Tulsa, OK, USA).
Variable 
No.
Variable
Name
Variable value for patient
No. 1 No. 2 No. 3 No. 4 No. 5 No. 6
1 Age (years) 54.6 63.9 44.2 37.9 74.8 79.7
2 Year of surgery 1988 1991 1989 1995 1994 1994
3 Place of residence 1 1 1 0 1 1
4 Marital status 0 1 2 1 2 0
5 Education 2 2 2 2 2 2
6 Professional activity 1 1 1 0 0 0
7 Blood group 3 1 1 1 0 0
8 Number of deliveries 2 1 1 1 1 5
9 Number of miscarriages 0 0 1 0 3 1
10 Age at ﬁ rst menstruation (years) 12 11 14 17 14 13
11 Age at last menstruation (years) 54 56 44 32 51 56
12 Post menopausal diagnosis 0 1 0 1 1 1
13 Obesity 1 1 0 1 0 0
14 Arterial hypertension 0 1 0 1 0 0
15 Diabetes mellitus 0 0 0 1 0 0
16 Endometriosis 1 1 1 2 1 1
17 Uterine myoma 0 0 0 0 1 0
18 Scrapings histological type 2 0 0 0 0 0
19 Histological type of post-operational material 1 1 2 9 1 1
20 Endometrial carcinoma histological grading 1 1 0 2 1 1
21 Endometrial carcinoma staging 1 1 1 6 2 5
22 Occurrence of other neoplasms 0 0 0 1 0 0
23 Kind of applied surgical treatment 0 0 0 4 4 1
24 Depth of myometrial invasion 1 1 1 1 2 1
25 Vascular space invasion 0 0 0 1 0 0
26 Colpitis 0 0 0 1 1 1
27 Category 1 1 1 0 0 0
Table 2. Variables considered in an analysis by an artiﬁ cial neural network (ANN) and their values for six exemplary patients.
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Figure 1. Architecture of the artiﬁ cial neural network used in predictions of survival in cases of endometrial carcinoma.
An artiﬁ cial neural network based on a multi-
player perceptron and consisting of 26 artiﬁ cial 
neurons in the input layer, 3 in a hidden lay-
er and 1 in the output layer was used. The ar-
chitecture of the model utilized is depicted in 
Figure 1. A supervised method of training with 
a back-propagation strategy was used. Variables 
from the patients analyzed were divided into three 
sets: a training set with 71 patients, a validating 
set with 25 patients and a testing set with 25 pa-
tients. Training the ANN was executed through 
3000 epochs, and the learning coefﬁ cient was 0.1; 
momentum equaled 0.3. Data from the training 
set was presented in a randomized manner dur-
ing the training process. The changes in RMS er-
ror were recorded for the training and validat-
ing sets during the training process (Figure 2). 
For further considerations, one takes the artiﬁ -
cial neural network with the lowest RMS error, 
with regards to the validating set of data. In this 
case, teaching the network was completed in 
1557 epochs.
PCA analysis
Principal component analysis of the 121×26 data 
matrix was performed by means of the Statistica 
computer program (StatSoft Inc, Tulsa, OK, 
USA), operated on a personal computer. It was 
found that two ﬁ rst principal components, PC1 
and PC2, cumulatively accounted for 23% of the 
total variance in the data described by 26 origi-
nal variables.
The projection of points assigned to individu-
al patients (principal component “scores”) in 
the space determined by the ﬁ rst two principal 
components axes, PC1 and PC2, is depicted in 
Figure 3.
The variables positioned in the space determined 
by the ﬁ rst principal components produce a plot 
of principal component “loadings”. The principal 
components most signiﬁ cant for separation of pa-
tients (“object scores”) in Figure 3 are PC1 and 
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Figure 4. A projection of 26 variables from Table 1 on the plane 
of PC1 and PC2 from a principal component analysis (PCA) of data 
for 121 patients.
Figure 5. Receiver Operating Characteristic curves (ROC curves) 
for the training set.
PC2. Therefore in Figure 4 the “loadings” of PC1 
and PC2 by individual variables are presented.
RESULTS AND DISCUSSION
Figure 1 presents the architecture of the ANN mod-
el used for predictions of 5-year survival of cancer 
patients, based on the input data from the training, 
validating and testing data sets, respectively.
In Table 3, classiﬁ cation statistics are collected 
for training, validating and testing sets and in 
Table 4 correlations between the variables consid-
ered, correlations between PCs and analyzed var-
iables, are presented. A summation of the princi-
pal component analysis is demonstrated in Table 
5. Receiver Operating Characteristic curve (ROC 
curve) for the training set is shown in Figure 5.
By using the proposed method, it was possible 
to differentiate the patients in the testing group 
as cases of survival or non-survival with no error. 
The prognostic potency of the ANN, with regard 
to the set of test patients, is excellent and proves 
a good choice of network and its form. All pa-
tients in the testing set, of total number of 25, 
were correctly classiﬁ ed, which means that one 
is able to predict the survival of patients with 
endometrial carcinoma, utilizing the selected 
variables, with very high probability.
Figure 2. Training Error Graph.
Figure 3. A projection of 121 points denoting patients (described 
by 26 variables listed in Table 1) in the space of the ﬁ rst two 
principal components, PC1 and PC2, and derived from a principal 
component analysis (PCA) of a 121×26 data matrix.
Original Paper Rep Pract Oncol Radiother, 2005; 10(5): 239-248
244
 
Training set Validating set Testing set
Lived Died Lived Died Lived Died
Total 52 19 19 6 20 5
Correct 50 18 18 6 20 5
Incorrect 2 1 1 0 0 0
Lived 50 1 18 0 20 0
Died 2 18 1 6 0 5
Table 3. Classiﬁ cation statistics.
Variable No.
1 2 3 4 5 6 7 8 9 10 11 12 13
PC 1 –0.806 0.074 –0.037 0.397 –0.203 0.538 0.093 –0.355 0.164 –0.019 –0.378 –0.720 –0.604
PC 2 –0.233 –0.518 –0.438 –0.119 0.217 0.376 –0.231 0.257 0.074 –0.067 –0.225 –0.192 –0.110
PC 3 –0.045 0.050 0.586 0.023 –0.465 0.211 0.125 –0.446 –0.304 –0.390 0.257 –0.082 0.119
PC 4 0.001 –0.659 0.092 0.077 0.112 –0.005 0.300 –0.057 0.092 –0.117 0.317 –0.047 –0.137
PC 5 0.002 –0.203 0.335 0.287 –0.384 0.148 –0.106 –0.240 0.208 –0.004 0.220 0.172 –0.156
PC 6 0.106 –0.125 0.134 –0.461 0.209 –0.005 –0.431 –0.262 –0.290 0.217 0.101 0.075 –0.277
PC 7 –0.010 0.086 0.095 0.055 0.030 0.083 0.079 –0.183 –0.504 –0.267 –0.184 0.140 0.120
PC 8 0.073 0.147 0.300 –0.194 –0.278 –0.006 –0.211 –0.023 –0.011 0.447 0.076 –0.080 –0.316
PC 9 0.137 –0.163 –0.003 –0.121 –0.307 0.248 0.437 0.092 –0.232 0.102 –0.291 0.201 0.112
PC 10 0.063 –0.144 0.128 –0.381 –0.149 –0.118 –0.112 –0.181 0.445 –0.432 –0.161 0.013 0.034
PC 11 0.129 –0.025 –0.052 0.225 0.128 –0.174 –0.021 –0.304 –0.110 0.240 –0.335 0.384 –0.080
PC 12 0.091 0.139 0.088 –0.205 0.309 –0.105 0.215 –0.089 –0.135 –0.248 0.287 –0.050 –0.098
PC 13 0.096 –0.049 0.151 0.117 0.169 –0.181 0.427 –0.223 0.322 0.156 –0.144 0.020 0.001
PC 14 0.086 0.078 –0.077 0.079 0.019 –0.132 0.056 0.224 0.128 –0.232 0.156 0.192 –0.404
PC 15 0.042 –0.069 0.009 –0.327 –0.202 –0.051 0.250 0.204 –0.062 0.212 0.007 –0.072 –0.083
PC 16 –0.256 0.020 –0.074 –0.144 –0.174 –0.411 0.074 –0.073 0.010 0.021 –0.132 –0.041 –0.188
PC 17 –0.114 0.081 0.063 0.029 –0.018 –0.001 –0.028 0.237 –0.040 –0.076 –0.033 0.006 0.116
PC 18 0.052 –0.082 0.051 –0.193 0.002 0.037 0.075 0.112 –0.085 –0.155 –0.285 –0.056 –0.070
PC 19 0.145 –0.057 0.132 –0.008 0.009 0.138 –0.212 0.045 0.162 –0.061 –0.208 0.186 –0.061
PC 20 –0.126 –0.098 0.145 0.036 0.058 –0.323 –0.152 –0.019 –0.092 –0.029 –0.136 –0.173 0.202
PC 21 0.006 0.086 0.183 0.181 –0.086 –0.131 –0.018 0.247 –0.073 –0.077 –0.066 0.058 –0.129
PC 22 –0.128 0.028 –0.017 –0.041 0.140 0.064 0.034 –0.077 –0.105 –0.117 –0.106 0.096 –0.215
PC 23 0.138 0.005 0.055 –0.014 –0.002 0.004 –0.028 0.038 0.071 –0.065 –0.085 –0.101 0.062
PC 24 –0.077 –0.095 0.282 0.007 0.225 0.070 0.042 0.127 0.006 0.107 –0.010 –0.047 –0.021
PC 25 –0.040 –0.280 –0.041 0.064 –0.069 –0.079 –0.044 0.029 –0.095 –0.022 0.073 0.075 –0.016
PC 26 –0.222 0.040 0.042 –0.093 0.003 0.026 0.012 0.024 0.076 0.017 0.038 0.202 0.098
Table 4. Correlations between PCs and analyzed variables.
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Variable No.
14 15 16 17 18 19 20 21 22 23 24 25 26
PC 1 –0.630 –0.475 0.147 0.034 0.148 –0.021 0.173 0.162 –0.033 0.329 0.203 0.087 0.162
PC 2 –0.133 0.115 –0.245 0.105 0.171 –0.153 –0.549 –0.681 –0.084 –0.469 –0.699 –0.236 0.160
PC 3 0.104 0.077 0.147 0.462 0.093 0.373 –0.300 –0.366 0.124 0.136 –0.388 0.132 –0.343
PC 4 –0.081 –0.124 –0.314 0.143 –0.190 0.203 0.263 0.153 –0.130 –0.585 0.150 0.591 –0.088
PC 5 0.245 –0.068 –0.118 –0.033 –0.532 –0.632 –0.092 0.078 0.168 –0.129 –0.014 –0.391 0.340
PC 6 –0.299 –0.297 0.201 –0.025 –0.019 –0.129 0.233 –0.168 0.397 –0.179 0.085 –0.144 –0.320
PC 7 0.163 –0.412 –0.358 –0.473 0.177 –0.186 0.174 –0.141 –0.376 –0.061 –0.065 –0.014 –0.004
PC 8 –0.046 0.274 –0.567 –0.024 0.304 0.194 –0.056 0.035 –0.198 –0.054 0.087 –0.021 0.181
PC 9 –0.139 0.090 0.107 –0.137 0.198 0.083 0.069 0.033 0.504 –0.150 0.056 0.025 0.375
PC 10 0.039 0.078 0.227 0.051 0.437 –0.179 0.191 0.083 –0.212 –0.115 0.060 –0.055 0.122
PC 11 –0.067 –0.045 0.053 0.515 0.070 –0.164 –0.045 –0.088 –0.184 0.060 –0.019 0.222 0.191
PC 12 –0.403 0.133 –0.028 –0.018 –0.140 –0.079 –0.078 0.030 –0.071 0.147 –0.139 –0.019 0.416
PC 13 –0.149 –0.016 –0.137 –0.118 0.047 0.100 0.008 –0.111 0.037 –0.006 –0.107 –0.379 –0.273
PC 14 0.154 –0.360 –0.160 0.093 0.268 0.060 –0.097 –0.044 0.288 0.129 –0.017 0.009 0.049
PC 15 0.085 –0.367 0.198 0.149 –0.157 0.046 –0.079 0.052 –0.335 0.024 –0.086 –0.146 0.032
PC 16 0.138 0.137 0.003 –0.182 –0.197 –0.039 0.141 –0.254 0.112 0.057 –0.161 0.236 0.033
PC 17 –0.062 0.020 –0.178 0.329 –0.068 0.027 0.510 –0.090 0.037 0.001 –0.111 –0.215 0.049
PC 18 –0.032 0.112 –0.259 0.133 –0.121 –0.240 –0.143 0.194 0.078 0.179 0.077 0.055 –0.272
PC 19 –0.088 –0.075 0.006 –0.160 –0.221 0.280 0.051 0.094 –0.040 0.137 –0.254 0.101 0.049
PC 20 0.009 –0.172 –0.066 0.042 0.015 0.137 –0.173 0.197 0.150 –0.089 –0.019 –0.083 0.163
PC 21 –0.203 0.069 0.159 –0.062 0.011 –0.067 –0.068 –0.028 –0.091 –0.210 0.025 –0.000 –0.098
PC 22 0.195 0.141 0.062 0.041 –0.097 0.210 –0.021 0.049 –0.044 –0.121 0.148 –0.192 0.036
PC 23 –0.021 –0.069 –0.039 0.013 –0.124 0.065 –0.050 –0.314 –0.007 0.038 0.299 0.019 0.090
PC 24 0.165 0.033 0.094 –0.030 0.089 –0.083 0.035 –0.055 0.015 0.107 –0.017 0.079 0.053
PC 25 –0.069 0.068 0.017 –0.046 0.050 0.050 0.016 –0.028 –0.067 0.211 0.074 –0.106 –0.011
PC 26 –0.077 –0.044 –0.045 –0.001 –0.012 0.001 –0.080 –0.024 –0.006 0.000 0.070 0.028 –0.017
Table 4 cont. Correlations between PCs and analyzed variables.
Principal component analysis also extracts system-
atic information on the variables considered. The 
most interesting are variables directly connected 
with a negative prognosis for 5 year post-operative 
survival: variable numbers: 3, 4, 5, 13, 14, 15, 16, 22, 
23, 25 and 26. These variables are located on the 
left side of Figure 4. Lower values for patients’ PC1 
and PC2 (closed circles in Figure 3) suggest that 
deterioration regarding surviving prevails among 
these patients. On the basis of that analysis it could 
be assumed that variable numbers: 3, 4, 5, 13, 14, 
15, 16, 22, 23, 25 and 26 have signiﬁ cant inﬂ uence 
on patients’ 5 year post-operative survival. These 
take into account variables such as place of resi-
dence, marital status, level of education, obesity, 
the coexistence of arterial hypertension, diabetes 
mellitus, endometriosis, colpitis or neoplastic dis-
eases other than endometrial cancer, as well as in-
formation regarding any kind of surgical treatment 
applied, or vascular space invasion.
CONCLUSIONS
The presented study is the ﬁ rst ever application 
of ANN and PCA to endometrial carcinoma out-
come prediction. It is mostly methodological in 
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No. of principal component Eigenvalue Variance accounted for (%) Total variance accounted for (%)
1 3.242 12.470 12.470
2 2.663 10.242 22.712
3 2.098 8.071 30.783
4 1.748 6.722 37.504
5 1.710 6.578 44.082
6 1.417 5.451 49.533
7 1.274 4.900 54.433
8 1.205 4.636 59.069
9 1.149 4.417 63.486
10 1.088 4.185 67.671
11 0.987 3.794 71.466
12 0.845 3.249 74.714
13 0.801 3.080 77.795
14 0.768 2.954 80.748
15 0.704 2.706 83.454
16 0.651 2.505 85.959
17 0.583 2.244 88.203
18 0.539 2.073 90.276
19 0.495 1.902 92.178
20 0.464 1.787 93.965
21 0.343 1.319 95.284
22 0.337 1.297 96.581
23 0.282 1.084 97.664
24 0.260 1.001 98.666
25 0.203 0.782 99.448
26 0.143 0.552 100.000
Table 5. Summation of the principal component analysis.
character and concerns a limited number of cas-
es. It may help to identify a combination of fac-
tors providing effective treatment and good prog-
nosis. Furthermore, the ANN and PCA analyses 
allow for testing a practically unlimited number 
of either mutually related or apparently unrelat-
ed factors and cases.
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